World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
27030
World Ranking
17902
National Ranking
8931

Overview

Ugo De Giorgi is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily spans the field of Medicine, with particular focus on several subfields, including Pulmonary and Respiratory Medicine, Oncology, Surgery, Cancer Research, and Radiology, Nuclear Medicine and Imaging.

De Giorgi's research topics cover various aspects of cancer treatment and diagnostics, highlighting areas such as Prostate Cancer Treatment and Research, Cancer Immunotherapy and Biomarkers, Renal Cell Carcinoma Treatment, Cancer Genomics and Diagnostics, Bladder and Urothelial Cancer Treatments, Radiopharmaceutical Chemistry and Applications, and PARP Inhibition in Cancer Therapy.

Their recent publications include the following papers:

  • Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma, 2021, New England Journal of Medicine
  • Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial, 2020, The Lancet
  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial, 2020, The Lancet Oncology
  • Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial, 2023, The Lancet
  • Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer, 2020, New England Journal of Medicine

De Giorgi has frequently published in several scientific journals, among which the most prolific venues include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • ESMO Open
  • Frontiers in Oncology
  • Cancers

The scientist has collaborated extensively with a number of frequent co-authors, with notable collaboration counts including:

  • Giuseppe Procopio (92 co-authored works)
  • Chiara Casadei (84 co-authored works)
  • Sebastiano Buti (79 co-authored works)
  • Giuseppe Fornarini (75 co-authored works)
  • Vincenza Conteduca (69 co-authored works)

Best Publications

  • Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

    Robert J. Motzer;Thomas E. Hutson;David Cella;James Reeves

  • Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

    Thomas Powles;Ignacio Durán;Michiel S van der Heijden;Yohann Loriot

  • Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

    Robert Motzer;Boris Alekseev;Sun Young Rha;Camillo Porta

  • Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    Brian I Rini;Thomas Powles;Michael B Atkins;Bernard Escudier

  • Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.

    Matthew D. Galsky;José Ángel Arranz Arija;Aristotelis Bamias;Ian D. Davis

  • Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study

    Bernard Escudier;Camillo Porta;Petri Bono;Thomas Powles

  • Plasma AR and abiraterone-resistant prostate cancer.

    Alessandro Romanel;Delila Gasi Tandefelt;Vincenza Conteduca;Anuradha Jayaram;Anuradha Jayaram

  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    Thomas Powles;Michiel S van der Heijden;Daniel Castellano;Matthew D Galsky

  • Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy

    Lorch A;Beyer J;Bascoul-Mollevi C

  • Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

    Cora N. Sternberg;Karim Fizazi;Fred Saad;Neal D. Shore

  • Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: Prognostic factors and role of postsurgery chemotherapy - Results from an international study group

    Karim Fizazi;Sergei Tjulandin;Roberto Salvioni;José R. Germà-Lluch

  • Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

    Robert John Motzer;Camillo Porta;Nicholas J Vogelzang;Cora N Sternberg

  • Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

    Robert L Coleman;Domenica Lorusso;Christine Gennigens;Antonio González-Martín

  • Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss

    Johann S de Bono;Ugo De Giorgi;Daniel Nava Rodrigues;Christophe Massard

  • Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment

    Mario Giuliano;Mario Giuliano;Mario Giuliano;Antonio Giordano;Antonio Giordano;Summer Jackson;Kenneth R Hess

  • Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database

    Anja Lorch;Caroline Bascoul-Mollevi;Andrew Kramar;Lawrence Einhorn

  • Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

    Matthew Smith;Johann De Bono;Cora Sternberg;Sylvestre Le Moulec

  • Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

    Sumanta K. Pal;Jonathan E. Rosenberg;Jean H. Hoffman-Censits;Raanan Berger

  • Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab.

    Ugo De Giorgi;Giuseppe Procopio;Diana Giannarelli;Roberto Sabbatini

  • Germ-cell tumors.

    Ugo De Giorgi;Paolo Pedrazzoli;Giovanni Rosti

Frequent Co-Authors

Daniele Santini
Daniele Santini Università Campus Bio-Medico
Cora N. Sternberg
Cora N. Sternberg Cornell University
Camillo Porta
Camillo Porta University of Bari Aldo Moro
Sandro Pignata
Sandro Pignata National Cancer Institute
Thomas Powles
Thomas Powles Queen Mary University of London
Dino Amadori
Dino Amadori University of Bologna
Giovanni Paganelli
Giovanni Paganelli Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Gerhardt Attard
Gerhardt Attard University College London
Ulka N. Vaishampayan
Ulka N. Vaishampayan University of Michigan–Ann Arbor
Joaquim Bellmunt
Joaquim Bellmunt Beth Israel Deaconess Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The journey to a medical career in the USA is evolving, with a growing number of online degrees offering flexibility and a wide range of options. For students interested in healthcare fields beyond the MD, several accredited programs can help you advance your career.

An important consideration is accreditation. Prospective healthcare administrators should explore which online healthcare degree programs are recognized for their accreditation by cahme? Choosing such programs ensures your education is respected by employers and meets industry standards.

Nurses seeking to upgrade their qualifications often ask: does rn to bsn require clinicals? Many online programs now offer flexible pathways that minimize or waive clinical components for experienced RNs, making advancement more accessible.

Advanced nursing degrees are also available online, with options to fast-track your credentials. Discover the shortest msn to dnp program for those looking to move quickly into leadership or advanced practice roles.

Flexibility is key, and some professionals may prefer online dnp programs without clinicals to balance work and studies.

Whether pursuing administration, nursing, or advanced medical education, these pathways offer varied and accessible routes to a rewarding healthcare career in the USA.

Best Scientists Citing Ugo De Giorgi

Trending Scientists

Recently Published Articles